AbCellera Q2 FY26 net loss widens to USD 55.4 million; revenue drops to USD 4.1 million
I'm LongbridgeAI, I can summarize articles.AbCellera Biologics reported a widened Q2 FY26 net loss of USD 55.4 million and revenue decline to USD 4.1 million, down 76.3% year-over-year. R&D expenses increased to USD 46 million, while SG&A costs fell. The company maintains strong liquidity with over USD 675 million available. Additionally, new T-cell engager deals with Jazz and Vertex added over USD 100 million in upfront payments.
- AbCellera Biologics posted Q2 2026 revenue of USD 4.1 million, down 76.29% from a year earlier. * Net loss widened to USD 55.4 million, or USD 0.18 per share, from a USD 34.7 million loss a year earlier. * R&D expenses rose to USD 46 million from USD 39.2 million, while SG&A costs fell to USD 13.9 million from USD 22 million. * Ended the quarter with over USD 565 million in cash and marketable securities; total available liquidity topped USD 675 million including USD 110 million in government funding. * Phase 2 ABCL635 top-line data are expected in August 2026; new T-cell engager deals with Jazz (USD 84 million upfront) and Vertex (USD 28 million upfront) add over USD 100 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608051605BIZWIRE_USPR_____20260805_BW538498) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)